{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:44:24Z","timestamp":1791229464799,"version":"4.1.0"},"reference-count":154,"publisher":"Oxford University Press (OUP)","issue":"31","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,14]]},"DOI":"10.1093\/eurheartj\/eht142","type":"journal-article","created":{"date-parts":[[2013,4,26]],"date-time":"2013-04-26T21:23:29Z","timestamp":1367011409000},"page":"2444-2452","source":"Crossref","is-referenced-by-count":335,"title":["Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II"],"prefix":"10.1093","volume":"34","author":[{"given":"Joshua A.","family":"Beckman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Paneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Creager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,4,26]]},"reference":[{"key":"key\n\t\t\t\t20170626082822_EHT142C1","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1161\/01.CIR.0000091257.27563.32","article-title":"Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I","volume":"108","author":"Creager","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626082822_EHT142C2","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1161\/01.CIR.0000089189.70578.E2","article-title":"Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part ii","volume":"108","author":"Luscher","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626082822_EHT142C3","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jama.289.1.76","article-title":"Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001","volume":"289","author":"Mokdad","year":"2003","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170626082822_EHT142C4","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1161\/CIRCULATIONAHA.106.613828","article-title":"Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study","volume":"113","author":"Fox","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626082822_EHT142C5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1464-5491.2011.03254.x","article-title":"Temporal trends in diabetes prevalence and key diabetes risk factors in Scotland, 2003\u20132008","volume":"28","author":"Hamer","year":"2011","journal-title":"Diabet Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1464-5491.2011.03446.x","article-title":"Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian population-based study","volume":"29","author":"Monesi","year":"2012","journal-title":"Diabet Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pcd.2012.05.002","article-title":"Prevalence and determinants of undiagnosed diabetes in an urban sub-Saharan African population","volume":"6","author":"Echouffo-Tcheugui","year":"2012","journal-title":"Primary Care Diabet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C8","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1464-5491.2005.01658.x","article-title":"Prevalence of Type 2 diabetes in urban and rural Chinese populations in Qingdao, China","volume":"22","author":"Dong","year":"2005","journal-title":"Diabet Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C9","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1464-5491.2009.02832.x","article-title":"Increasing trend in the prevalence of Type 2 diabetes and pre-diabetes in the Chinese rural and urban population in Qingdao, China","volume":"26","author":"Gao","year":"2009","journal-title":"Diabet Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C10","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00125-004-1387-6","article-title":"Temporal changes in prevalence of diabetes and impaired glucose tolerance associated with lifestyle transition occurring in the rural population in India","volume":"47","author":"Ramachandran","year":"2004","journal-title":"Diabetologia"},{"issue":"Suppl. 5","key":"key\n\t\t\t\t20170626082822_EHT142C11","first-page":"S1","article-title":"The rising global burden of diabetes and its complications: estimates and projections to the year 2010","volume":"14","author":"Amos","year":"1997","journal-title":"Diabet Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C12","volume-title":"In: Fact Sheet","author":"World Health Organization","year":"2011"},{"key":"key\n\t\t\t\t20170626082822_EHT142C13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2012.39","article-title":"Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999\u20132010","volume":"307","author":"Flegal","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170626082822_EHT142C14","first-page":"E114","article-title":"Incidence of self-reported diabetes in new york city, 2002, 2004, and 2008","volume":"9","author":"Tabaei","year":"2012","journal-title":"Prevent Chronic Disease"},{"key":"key\n\t\t\t\t20170626082822_EHT142C15","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.3945\/jn.109.112029","article-title":"Nationally representative surveys show recent increases in the prevalence of overweight and obesity among women of reproductive age in Bangladesh, Nepal, and India","volume":"139","author":"Balarajan","year":"2009","journal-title":"J Nutrition"},{"key":"key\n\t\t\t\t20170626082822_EHT142C16","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1467-789X.2011.00943.x","article-title":"Age standardization in mapping adult overweight and obesity trends in the WHO European Region","volume":"13","author":"Doak","year":"2012","journal-title":"Obesity Rev"},{"key":"key\n\t\t\t\t20170626082822_EHT142C17","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ahj.2010.10.019","article-title":"A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design","volume":"161","author":"Preiss","year":"2011","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170626082822_EHT142C18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/JAHA.111.000059","article-title":"Mortality rates in trials of subjects with type 2 diabetes","volume":"1","author":"Barkoudah","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t20170626082822_EHT142C19","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C20","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/S0140-6736(00)04774-7","article-title":"Properties of olive oil","volume":"357","author":"Wahrburg","year":"2001","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C21","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.107.720847","article-title":"Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people","volume":"117","author":"Schramm","year":"2008","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626082822_EHT142C22","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1464-5491.2008.02640.x","article-title":"Is diabetes a coronary risk equivalent? Systematic review and meta-analysis","volume":"26","author":"Bulugahapitiya","year":"2009","journal-title":"Diabet Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C23","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.2337\/diacare.20.7.1183","article-title":"Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus","volume":"20","author":"Gavin","year":"1997","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170626082822_EHT142C24","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/S0140-6736(02)09089-X","article-title":"Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study","volume":"359","author":"Norhammar","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C25","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.ehj.2004.07.027","article-title":"The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart","volume":"25","author":"Bartnik","year":"2004","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626082822_EHT142C26","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/heartjnl-2012-301629","article-title":"Newly diagnosed glucose intolerance and prognosis after acute myocardial infarction: comparison of post-challenge versus fasting glucose concentrations","volume":"98","author":"Tamita","year":"2012","journal-title":"Heart"},{"key":"key\n\t\t\t\t20170626082822_EHT142C27","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170626082822_EHT142C28","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","article-title":"Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38","volume":"118","author":"Wiviott","year":"2008","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626082822_EHT142C29","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.amjcard.2011.10.018","article-title":"Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction","volume":"109","author":"Jensen","year":"2012","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170626082822_EHT142C30","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/CIRCULATIONAHA.105.600155","article-title":"Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents","volume":"113","author":"Kuchulakanti","year":"2006","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626082822_EHT142C31","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jacc.2007.04.051","article-title":"Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry","volume":"50","author":"Machecourt","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626082822_EHT142C32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/CIRCULATIONAHA.109.903955","article-title":"Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART)","volume":"122","author":"Kimura","year":"2010","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626082822_EHT142C33","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2011.1529","article-title":"Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis","volume":"306","author":"Cayla","year":"2011","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170626082822_EHT142C34","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1378\/chest.126.6.1789","article-title":"The influence of type 2 diabetes mellitus in patients undergoing coronary artery bypass graft surgery: an 8-year prospective cohort study","volume":"126","author":"Woods","year":"2004","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170626082822_EHT142C35","doi-asserted-by":"crossref","first-page":"I220","DOI":"10.1161\/CIRCULATIONAHA.106.681320","article-title":"Long-term impact of diabetes and its comorbidities in patients undergoing isolated primary coronary artery bypass graft surgery","volume":"116","author":"Mohammadi","year":"2007","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626082822_EHT142C36","doi-asserted-by":"crossref","first-page":"II41","DOI":"10.1161\/01.CIR.0000138197.07051.e7","article-title":"Effect of diabetes and associated conditions on long-term survival after coronary artery bypass graft surgery","volume":"110","author":"Leavitt","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626082822_EHT142C37","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1475-2840-6-25","article-title":"Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998\u20132004: a longitudinal observational study","volume":"6","author":"Greving","year":"2007","journal-title":"Cardiovasc Diabetol"},{"key":"key\n\t\t\t\t20170626082822_EHT142C38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1464-5491.2011.03425.x","article-title":"Time trends in absolute and modifiable coronary heart disease risk in patients with Type 2 diabetes in the Swedish National Diabetes Register (NDR) 2003\u20132008","volume":"29","author":"Fharm","year":"2012","journal-title":"Diabet Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1753-0407.2011.00148.x","article-title":"Trends in the control of risk factors for cardiovascular disease among adults with diagnosed diabetes: findings from the National Health and Nutrition Examination Survey 1999\u20132008*","volume":"3","author":"Ford","year":"2011","journal-title":"J Diab"},{"key":"key\n\t\t\t\t20170626082822_EHT142C40","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2337\/dc10-2251","article-title":"Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: findings from the National Health and Nutrition Examination Survey, 1999\u20132008","volume":"34","author":"Ford","year":"2011","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170626082822_EHT142C41","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.2337\/dc11-1162","article-title":"Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey","volume":"35","author":"Gregg","year":"2012","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170626082822_EHT142C42","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCULATIONAHA.108.829176","article-title":"Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005","volume":"119","author":"Preis","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626082822_EHT142C43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"Collins","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C44","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2337\/dc06-2363","article-title":"Prospective study of type 1 and type 2 diabetes and risk of stroke subtypes: the Nurses' Health Study","volume":"30","author":"Janghorbani","year":"2007","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170626082822_EHT142C45","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1159\/000155989","article-title":"Trends in risk factors, stroke subtypes and outcome. Nineteen-year data from the Sagrat Cor Hospital of Barcelona stroke registry","volume":"26","author":"Arboix","year":"2008","journal-title":"Cerebrovasc Dis"},{"key":"key\n\t\t\t\t20170626082822_EHT142C46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0140-6736(10)60834-3","article-title":"Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study","volume":"376","author":"O'Donnell","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C47","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","article-title":"Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies","volume":"375","author":"Sarwar","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C48","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1212\/01.wnl.0000280457.29680.9c","article-title":"Association of diabetes, homocysteine, and HDL with cognition and disability after stroke","volume":"69","author":"Newman","year":"2007","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20170626082822_EHT142C49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1212\/WNL.0b013e31824367ab","article-title":"Functional recovery after ischemic stroke\u2013a matter of age: data from the Austrian Stroke Unit Registry","volume":"78","author":"Knoflach","year":"2012","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20170626082822_EHT142C50","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1161\/STROKEAHA.111.621649","article-title":"Diabetes and poor outcomes within 6 months after acute ischemic stroke: the China National Stroke Registry","volume":"42","author":"Jia","year":"2011","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170626082822_EHT142C51","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1016\/S0140-6736(05)66734-7","article-title":"Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study","volume":"365","author":"van Wijk","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1747-4949.2010.00567.x","article-title":"Prognosis of ischaemic stroke is improving similarly in patients with type 2 diabetes as in nondiabetic patients in Finland","volume":"6","author":"Winell","year":"2011","journal-title":"Int J Stroke"},{"key":"key\n\t\t\t\t20170626082822_EHT142C53","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1007\/s00125-011-2262-x","article-title":"Trends in population attributable fraction of acute coronary syndrome and ischaemic stroke due to diabetes in Finland","volume":"54","author":"Winell","year":"2011","journal-title":"Diabetologia"},{"key":"key\n\t\t\t\t20170626082822_EHT142C54","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/aje\/kwj124","article-title":"Trends in the prevalence, awareness, treatment, and control of cardiovascular disease risk factors among noninstitutionalized patients with a history of myocardial infarction and stroke","volume":"163","author":"Muntner","year":"2006","journal-title":"Am J Epidemiol"},{"key":"key\n\t\t\t\t20170626082822_EHT142C55","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1161\/STROKEAHA.109.550814","article-title":"Stroke incidence and mortality rates 1987 to 2006 related to secular trends of cardiovascular risk factors in Gothenburg, Sweden","volume":"40","author":"Harmsen","year":"2009","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170626082822_EHT142C56","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.2337\/diacare.26.12.3357","article-title":"High prevalence of peripheral arterial disease but low antiplatelet treatment rates in elderly primary care patients with diabetes","volume":"26","author":"Lange","year":"2003","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170626082822_EHT142C57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0021-9150(03)00204-1","article-title":"High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study","volume":"172","author":"Diehm","year":"2004","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20170626082822_EHT142C58","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ejim.2011.02.001","article-title":"Prevalence and clinical profile and management of peripheral arterial disease in elderly patients with diabetes","volume":"22","author":"Escobar","year":"2011","journal-title":"Eur J Intern Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C59","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1067\/mva.2001.119749","article-title":"Natural history of claudication: long-term serial follow-up study of 1244 claudicants","volume":"34","author":"Aquino","year":"2001","journal-title":"J Vasc Surg"},{"key":"key\n\t\t\t\t20170626082822_EHT142C60","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.diabres.2007.01.010","article-title":"Incidence of critical limb ischemia and amputation outcome in contralateral limb in diabetic patients hospitalized for unilateral critical limb ischemia during 1999\u20132003 and followed-up until 2005","volume":"77","author":"Faglia","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"key\n\t\t\t\t20170626082822_EHT142C61","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1464-5491.2009.02866.x","article-title":"Peripheral arterial disease in diabetes\u2013a review","volume":"27","author":"Jude","year":"2010","journal-title":"Diabet Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C62","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.2337\/dc11-0903","article-title":"Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: the ADDITION-Denmark study","volume":"34","author":"Charles","year":"2011","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170626082822_EHT142C63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1071\/AH10969","article-title":"Diabetes-related major lower limb amputation in Far North Queensland, 1998\u20132008","volume":"36","author":"O'Rourke","year":"2012","journal-title":"Aust Health Rev"},{"key":"key\n\t\t\t\t20170626082822_EHT142C64","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.2337\/dc10-1775","article-title":"Trends in initial lower extremity amputation rates among Veterans Health Administration health care System users from 2000 to 2004","volume":"34","author":"Tseng","year":"2011","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170626082822_EHT142C65","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.2337\/dc11-0077","article-title":"Trends in lower-extremity amputations in people with and without diabetes in Spain, 2001\u20132008","volume":"34","author":"Lopez-de-Andres","year":"2011","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170626082822_EHT142C66","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2337\/dc11-1360","article-title":"Declining rates of hospitalization for nontraumatic lower-extremity amputation in the diabetic population aged 40 years or older: U.S., 1988\u20132008","volume":"35","author":"Li","year":"2012","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170626082822_EHT142C67","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2337\/diacare.22.2.233","article-title":"The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years","volume":"22","author":"Coutinho","year":"1999","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170626082822_EHT142C68","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C69","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","author":"Turner","year":"1998","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C70","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C71","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl JiMed"},{"key":"key\n\t\t\t\t20170626082822_EHT142C72","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C73","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C74","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C75","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jacc.2008.10.008","article-title":"Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association","volume":"53","author":"Skyler","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626082822_EHT142C76","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C77","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Metformin use and mortality among patients with diabetes and atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C78","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/eurheartj\/ehr077","article-title":"Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study","volume":"32","author":"Schramm","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626082822_EHT142C79","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170626082822_EHT142C80","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","article-title":"Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality","volume":"170","author":"Nissen","year":"2010","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C81","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170626082822_EHT142C82","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","article-title":"Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes","volume":"27","author":"Timmis","year":"2006","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626082822_EHT142C83","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","article-title":"Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial","volume":"119","author":"Morrow","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626082822_EHT142C84","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrd2823","article-title":"Regulatory watch: FDA issues guidance for cardiovascular risk assessment of novel antidiabetic agents","volume":"8","year":"2009","journal-title":"Nat Rev Drug Disc"},{"key":"key\n\t\t\t\t20170626082822_EHT142C85","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group","volume":"317","author":"Robert","year":"1998","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170626082822_EHT142C86","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","article-title":"Long-term follow-up after tight control of blood pressure in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C87","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C88","doi-asserted-by":"crossref","first-page":"9R","DOI":"10.1016\/S0002-9149(98)00750-4","article-title":"Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial","volume":"82","author":"Estacio","year":"1998","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170626082822_EHT142C89","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","author":"Chobanian","year":"2004"},{"key":"key\n\t\t\t\t20170626082822_EHT142C90","doi-asserted-by":"crossref","first-page":"44i","DOI":"10.1016\/j.amjcard.2007.03.005","article-title":"Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial","volume":"99","author":"Cushman","year":"2007","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170626082822_EHT142C91","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C92","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"Furberg","year":"2002","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170626082822_EHT142C93","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.amjcard.2007.05.057","article-title":"A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus","volume":"100","author":"Bangalore","year":"2007","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170626082822_EHT142C94","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/eurheartj\/ehl001","article-title":"Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology","volume":"27","author":"Fox","year":"2006","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626082822_EHT142C95","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C96","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C97","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C98","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/eurheartj\/ehi225","article-title":"The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy","volume":"26","author":"Daly","year":"2005","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626082822_EHT142C99","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/00000539-200109000-00029","article-title":"Differential secretion of atrial and brain natriuretic peptide in critically ill patients","volume":"93","author":"Berendes","year":"2001","journal-title":"Anesth Analg"},{"key":"key\n\t\t\t\t20170626082822_EHT142C100","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0002-8703(96)90559-1","article-title":"Angiotensin-converting enzyme inhibition after myocardial infarction: the Trandolapril Cardiac Evaluation Study","volume":"132","author":"Torp-Pedersen","year":"1996","journal-title":"Am Heart J"},{"issue":"Suppl. B","key":"key\n\t\t\t\t20170626082822_EHT142C101","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/eurheartj\/15.suppl_B.2","article-title":"Uniformity of captopril benefit in the SAVE Study: subgroup analysis. Survival and Ventricular Enlargement Study","volume":"15","author":"Moye","year":"1994","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626082822_EHT142C102","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1161\/01.CIR.96.12.4239","article-title":"Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study","volume":"96","author":"Zuanetti","year":"1997","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626082822_EHT142C103","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.amjcard.2007.06.049","article-title":"Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease","volume":"100","author":"Arca","year":"2007","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170626082822_EHT142C104","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C105","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1126\/science.1156675","article-title":"Probing cold dense nuclear matter","volume":"320","author":"Subedi","year":"2008","journal-title":"Science"},{"key":"key\n\t\t\t\t20170626082822_EHT142C106","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S0140-6736(02)08090-X","article-title":"Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Lindholm","year":"2002","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C107","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C108","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C109","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C110","first-page":"133","article-title":"Spironolactone in patients with heart failure","volume":"342","author":"Pitt","year":"2000","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C111","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C112","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C113","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of valsartan on the incidence of diabetes and cardiovascular events","volume":"362","author":"McMurray","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C114","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C115","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C116","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C117","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2337\/diacare.28.5.1151","article-title":"Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial\u2013lipid-lowering arm (ASCOT-LLA)","volume":"28","author":"Sever","year":"2005","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170626082822_EHT142C118","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C119","doi-asserted-by":"crossref","first-page":"614","DOI":"10.2337\/diacare.20.4.614","article-title":"Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)","volume":"20","author":"Pyorala","year":"1997","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170626082822_EHT142C120","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.2337\/diacare.26.10.2713","article-title":"Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial","volume":"26","author":"Keech","year":"2003","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170626082822_EHT142C121","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/archneurol.2011.146","article-title":"Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial","volume":"68","author":"Callahan","year":"2011","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20170626082822_EHT142C122","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C123","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C124","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0025-6196(11)60763-5","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease","volume":"83","author":"Shepherd","year":"2008","journal-title":"Mayo Clinic Proc"},{"key":"key\n\t\t\t\t20170626082822_EHT142C125","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1093\/eurheartj\/ehl220","article-title":"Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626082822_EHT142C126","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C127","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C128","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","article-title":"Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial","volume":"373","author":"Rajamani","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C129","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C130","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMc1006407","article-title":"Combination lipid therapy in type 2 diabetes","volume":"363","author":"Sacks","year":"2010","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C131","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C132","doi-asserted-by":"crossref","first-page":"396","DOI":"10.7326\/0003-4819-150-6-200903170-00008","article-title":"Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement","volume":"150","author":"Calonge","year":"2009","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C133","doi-asserted-by":"crossref","first-page":"e637S","DOI":"10.1378\/chest.11-2306","article-title":"Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Vandvik","year":"2012","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170626082822_EHT142C134","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C135","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.amjcard.2011.02.325","article-title":"Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin","volume":"107","author":"Bartolucci","year":"2011","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170626082822_EHT142C136","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.amjmed.2011.01.018","article-title":"Effect of aspirin on mortality in the primary prevention of cardiovascular disease","volume":"124","author":"Raju","year":"2011","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C137","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Baigent","year":"2002","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170626082822_EHT142C138","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1001\/jama.2008.623","article-title":"Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial","volume":"300","author":"Ogawa","year":"2008","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170626082822_EHT142C139","doi-asserted-by":"crossref","first-page":"a1840","DOI":"10.1136\/bmj.a1840","article-title":"The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease","volume":"337","author":"Belch","year":"2008","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170626082822_EHT142C140","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2337\/dc10-0555","article-title":"Aspirin for primary prevention of cardiovascular events in people with diabetes","volume":"22","author":"Pignone","year":"2010","journal-title":"Diabetes Care"},{"key":"key\n\t\t\t\t20170626082822_EHT142C141","first-page":"349","article-title":"Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group","volume":"2","author":"Hunt","year":"1988","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C142","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"Gent","year":"1996","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626082822_EHT142C143","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9149(02)02567-5","article-title":"Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus","volume":"90","author":"Bhatt","year":"2002","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170626082822_EHT142C144","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C145","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C146","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C147","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1093\/eurheartj\/ehq325","article-title":"Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"31","author":"James","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626082822_EHT142C148","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C149","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C150","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.2009.476","article-title":"Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial","volume":"301","author":"Young","year":"2009","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170626082822_EHT142C151","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s11906-012-0314-3","article-title":"Blood pressure j-curve: current concepts","volume":"14","author":"Banach","year":"2012","journal-title":"Curr Hypertens Rep"},{"key":"key\n\t\t\t\t20170626082822_EHT142C152","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa070829","article-title":"Optimal medical therapy with or without PCI for stable coronary disease","volume":"356","author":"Boden","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C153","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","article-title":"A randomized trial of therapies for type 2 diabetes and coronary artery disease","volume":"360","author":"Frye","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626082822_EHT142C154","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1211585","article-title":"Strategies for multivessel revascularization in patients with diabetes","volume":"367","author":"Farkouh","year":"2012","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/34\/31\/2444\/17896056\/eht142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,22]],"date-time":"2017-08-22T21:22:28Z","timestamp":1503436948000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/eht142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,26]]},"references-count":154,"journal-issue":{"issue":"31","published-online":{"date-parts":[[2013,4,26]]},"published-print":{"date-parts":[[2013,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/eht142","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4,26]]}}}